CS logo
small CS logo
Michiana Hematology Oncology PC-Plymouth

Plymouth, Indiana, United States
Cancer treatment center in Plymouth, Indiana
1915 Lake Ave, Plymouth, IN 46563

About Michiana Hematology Oncology PC-Plymouth


  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Michiana Hematology Oncology PC-Plymouth


During the past decade, Michiana Hematology Oncology PC-Plymouth conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 92 clinical trials were completed, i.e. on average, 657.1% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 38 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Michiana Hematology Oncology PC-Plymouth" #1 sponsor was "National Cancer Institute (NCI)" with 49 trials, followed by "Alliance for Clinical Trials in Oncology" with 37 trials sponsored, "SWOG Cancer Research Network" with 14 trials sponsored, "Gynecologic Oncology Group" with 12 trials sponsored and "ECOG-ACRIN Cancer Research Group" with 12 trials sponsored. Other sponsors include 4 different institutions and companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Michiana Hematology Oncology PC-Plymouth" #1 collaborator was "National Cancer Institute (NCI)" with 76 trials as a collaborator, "NRG Oncology" with 16 trials as a collaborator, "SWOG Cancer Research Network" with 7 trials as a collaborator, "NCIC Clinical Trials Group" with 6 trials as a collaborator and "Cancer and Leukemia Group B" with 5 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 19 trials.

Clinical Trials Conditions at Michiana Hematology Oncology PC-Plymouth


According to Clinical.Site data, the most researched conditions in "Michiana Hematology Oncology PC-Plymouth" are "Breast Cancer" (16 trials), "Stage IV Fallopian Tube Cancer AJCC v6 and v7" (8 trials), "Stage IV Ovarian Cancer AJCC v6 and v7" (8 trials), "Colorectal Cancer" (7 trials) and "Recurrent Ovarian Carcinoma" (7 trials). Many other conditions were trialed in "Michiana Hematology Oncology PC-Plymouth" in a lesser frequency.

Clinical Trials Intervention Types at Michiana Hematology Oncology PC-Plymouth


Most popular intervention types in "Michiana Hematology Oncology PC-Plymouth" are "Drug" (102 trials), "Other" (96 trials), "Biological" (44 trials), "Procedure" (19 trials) and "Radiation" (10 trials). Other intervention types were less common.
The name of intervention was led by "Laboratory Biomarker Analysis" (55 trials), "Quality-of-Life Assessment" (29 trials), "Paclitaxel" (22 trials), "Bevacizumab" (20 trials) and "placebo" (20 trials). Other intervention names were less common.

Clinical Trials Genders at Michiana Hematology Oncology PC-Plymouth


The vast majority of trials in "Michiana Hematology Oncology PC-Plymouth" are 80 trials for "All" genders, 41 trials for "Female" genders and 4 trials for "Male" genders.

Clinical Trials Status at Michiana Hematology Oncology PC-Plymouth


Currently, there are NaN active trials in "Michiana Hematology Oncology PC-Plymouth". undefined are not yet recruiting, 3 are recruiting, 48 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 59 completed trials in Michiana Hematology Oncology PC-Plymouth, undefined suspended trials, and 10 terminated clinical trials to date.
Out of the total trials that were conducted in Michiana Hematology Oncology PC-Plymouth, 6 "Phase 1" clinical trials were conducted, 40 "Phase 2" clinical trials and 73 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".